Abstract:Proteolysis targeting chimera (PROTAC) technology, a groundbreaking strategy for degradation of pathogenic proteins by hijacking of the ubiquitin-proteasome-system has become a promising strategy in drug design. However, the real-time monitoring and visualization of protein degradation processes have been long-standing challenges in the realm of drug development. In this research, we sought to amalgamate the highly efficient protein-degrading capabilities of PROTAC technology with the visualization attributes of fluorescent probes, with the potential to pave the path for the design and development of a novel class of visual PROTACs. These novel PROTACs uniquely possess both fluorescence imaging and therapeutic characteristics, all with the goal of enabling real-time observations of protein degradation processes. Our approach involved the utilization of a high ER-targeting fluorescent probe, previously reported in our laboratory, which served as a warhead that specifically binds to the protein of interest (POI). Additionally, a VHL ligand for recruiting E3 ligase and linkers of various lengths were incorporated to synthesize a series of novel ER-inherent fluorescence PROTACs. Among them, compound A3 demonstrated remarkable efficiency in degrading ERα proteins (DC 50 = 0.12 μM) and displaying exceptional anti-proliferative activity against MCF-7 cells (IC 50 = 0.051 μM). Furthermore, it exhibited impressive fluorescence imaging performance, boasting an emission wavelength of up to 582 nm, a Stokes shift of 116 nm, and consistent optical properties. These attributes make it especially suitable for the real-time, in situ tracking of ERα protein degradation processes, thus may serve as a privileged visual theranostic PROTAC for ERα + breast cancer. This study not only broadens the application spectrum of PROTAC technology but also introduces a novel approach for real-time visualization of protein degradation processes, ultimately enhancing the diagnostic and treatment efficacy of PROTACs.

ERα-Targeting PROTAC As a Chemical Knockdown Tool to Investigate the Estrogen Receptor Function in Rat Menopausal Arthritis

PROTAC Degrader of Estrogen Receptor Α Targeting DNA-Binding Domain in Breast Cancer.

Development of Stabilized Peptide-Based PROTACs Against Estrogen Receptor Α

PROTACs: an Emerging Targeting Technique for Protein Degradation in Drug Discovery

Overview of PROTACs Targeting the Estrogen Receptor: Achievements for Biological and Drug Discovery

Discovery of ERD-12310A As an Exceptionally Potent and Orally Efficacious PROTAC Degrader of Estrogen Receptor Α (Erα)

Abstract 6577: Chemoproteomic evaluation of PROTACs targeting estrogen receptor alpha for ER+ breast cancer

Targeting estrogen receptor α for degradation with PROTACs: A promising approach to overcome endocrine resistance

Abstract 4510: Potent and orally efficacious PROTAC degraders of estrogen receptor α (ERα)

Targeting androgen receptor and the variants by an orally bioavailable Proteolysis Targeting Chimeras compound in castration resistant prostate cancer

Antagonism of estrogen-mediated cell proliferation by raloxifene in prevention of ageing-related prostatic hyperplasia.

Discovery of ERD-3111 as a Potent and Orally Efficacious Estrogen Receptor PROTAC Degrader with Strong Antitumor Activity

Estrogen Prevents Articular Cartilage Destruction in a Mouse Model of AMPK Deficiency Via ERK-mTOR Pathway

Strategies Toward Discovery of Potent and Orally Bioavailable Proteolysis Targeting Chimera Degraders of Androgen Receptor for the Treatment of Prostate Cancer.

Metabolism-driven in vitro/in vivo disconnect of an oral ERɑ VHL-PROTAC

De Novo Design of an Androgen Receptor DNA Binding Domain‐Targeted peptide PROTAC for Prostate Cancer Therapy

Designed, synthesized and biological evaluation of proteolysis targeting chimeras (PROTACs) as AR degraders for prostate cancer treatment

Glutathione-responsive PROTAC for targeted degradation of ERα in breast cancer cells

Fluorescence theranostic PROTACs for real-time visualization of ERα degradation

A modular PROTAC design for target destruction using a degradation signal based on a single amino acid

PROTAC: An Effective Targeted Protein Degradation Strategy for Cancer Therapy